Juan Manuel Dominguez-Salgado

Juan Manuel Dominguez-Salgado

Auto-generated profile, based on publicly available information

Juan Manuel Dominguez-Salgado


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MLMardia López-Alarcón
Mardia López-Alarcón
VVVíctor Saúl Vital-Reyes
Víctor Saúl Vital-Reyes
Eduardo Almeida-GutierrezEduardo Almeida-Gutierrez
Eduardo Almeida-Gutierrez
Jorge Maldonado-HernándezJorge Maldonado-Hernández
Jorge Maldonado-Hernández
SFSalvador Flores-Chávez
Salvador Flores-Chávez
RZRicardo Z’cruz-López
Ricardo Z’cruz-López
Polycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without PCOS were evaluated. The clinical biomarkers of alterations related to glucose (glucose, insulin, and clamp-derived glucose disposal − M), liver (aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase), and endothelium (arginine, asymmetric dymethylarginine, carotid intima-media thickness, and flow-mediated dilation) metabolism were measured; participants were categorized into four groups according to their obesity (OB) and hyperandrogenemia (HA) status as follows: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were very frequent in women with PCOS (≈70%). BMI correlated with all biomarkers, whereas free testosterone (FT) correlated with only glucose- and liver-related indicators. Although insulin sensitivity and liver enzymes were associated with FT, women with obesity showed lower M (coef = 8.56 − 0.080(FT) − 3.71(Ob); p < 0.001) and higher aspartate aminotransferase (coef = 26.27 + 0.532 (FT) + 8.08 (Ob); p = 0.015) than lean women with the same level of FT. Women with obesity showed a higher risk of metabolic disorders than lean women, independent of hyperandrogenemia. Clinicians are compelled to look for metabolic alterations in women with PCOS. Obesity should be treated in all cases, but hyperandrogenemia should also be monitored in those with glucose-or liver-related disturbances.

10 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
Rocio Ortiz MRocio Ortiz M
Rocio Ortiz M
Jorge Maldonado-HernándezJorge Maldonado-Hernández
Jorge Maldonado-Hernández
JMJorge A. Martin-Trejo
Jorge A. Martin-Trejo
MRMaría E. Rodríguez-Palacios
María E. Rodríguez-Palacios
Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption, and disruptions in this complex can affect bone metabolism. Methods: This study analyzes the changes in RANKL, OPG, and 25(OH)D levels; the RANKL/OPG ratio; and other bone turnover markers (BTMs) from diagnosis to complete remission in children with acute lymphoblastic leukemia (ALL). This is a prospective observational cohort study, carried out at the Instituto Mexicano del Seguro Social, Mexico City, including 33 patients (4–17 years) with newly diagnosed B-cell ALL. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A peripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p = 0.001) and osteocalcin (p < 0.001) levels and RANKL/OPG ratio (<0.001) and a decreased OPG level (p = 0.005) were observed at remission, predominantly in the high-risk (HR) relapse and vitamin D deficiency groups. A negative association between RANKL and OPG (r = −0.454, p = 0.008) was observed. Conclusions: we suggest that the RANKL/OPG ratio could serve as a bone remodeling marker in ALL patients.

20 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
Rocio Ortiz MRocio Ortiz M
Rocio Ortiz M
Jorge Maldonado-HernándezJorge Maldonado-Hernández
Jorge Maldonado-Hernández
JMJorge A Martin-Trejo
Jorge A Martin-Trejo
MRMaría E Rodríguez-Palacios
María E Rodríguez-Palacios
Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption; disruptions in this complex can affect bone metabolism. Methods: This study analyzed the changes in RANKL, OPG and 25(OH)D levels, the RANKL/OPG ratio, and other bone turnover markers (BTM) from diagnosis to complete remission in children with acute lym-phoblastic leukemia (ALL). This is a prospective observational cohort study. This study was carried out in the Instituto Mexicano del Seguro Social in Mexico City. Thirty-three patients (4-17 years) with newly diagnosed B-cell ALL were included. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A pe-ripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p=0.001) and osteocalcin (p

31 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
IZImelda Cecilia Zarzoza-Mendoza
Imelda Cecilia Zarzoza-Mendoza
MRMaricela Rodríguez-Cruz
Maricela Rodríguez-Cruz
MCM. Cristina Carmona-Isunza
M. Cristina Carmona-Isunza
HSHilda Sánchez-Vidal
Hilda Sánchez-Vidal
JFJosé Carlos Páez Franco
José Carlos Páez Franco
LBLourdes Barbosa-Cortés
Lourdes Barbosa-Cortés
Background/Objective: Human milk is an irreplaceable source of nutrition and is essential for the infant’s growth and development right after birth and for early life stage survival. This study aims to characterize and compare the metabolite profiles of colostrum and transitional and mature milk using an untargeted GC-MS approach. Additionally, it explores potential correlations between the identified metabolites and maternal nutritional factors. Methods: This was a longitudinal, prospective, and observational study. We included human milk samples from 113 Mexican women who practiced exclusive breastfeeding. Partial least squares-discriminant analysis (PLS-DA) was performed to assess differences among lactation stages. Metabolites showing significant variation across lactation stages were further analyzed using Friedman tests with post hoc Wilcoxon tests and Bonferroni correction. Correlations with maternal anthropometric measures were evaluated. Results: Twenty-three metabolites were identified, including amino acids and derivatives, sugars, fatty acids, and energetic metabolites. Alanine and creatinine levels decreased during lactation, while aspartate, serine, and valine levels increased. Rhamnose level was higher in colostrum, whereas decanoic, dodecanoic, and tetradecanoic acid levels increased over time, and that of 11,14-eicosadienoic acid decreased. Lactic acid levels declined across stages. Negative correlations were found between several amino acids and maternal anthropometric variables, while glyceric acid, rhamnose and lactic acid correlated positively. Conclusions: Human milk metabolomic profiles display distinct, stage-specific variations shaped by maternal characteristics, reflecting the dynamic physiological and nutritional demands of the developing infant

31 July 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MBMaria de Lourdes Barbosa-Cortes
Maria de Lourdes Barbosa-Cortes
SMSharon Morales-Montes
Sharon Morales-Montes
MMMichelle Maldonado-Alvarado
Michelle Maldonado-Alvarado
JMJorge A. Martin-Trejo
Jorge A. Martin-Trejo
SASalvador Atilano-Miguel
Salvador Atilano-Miguel
IDIsrael Domínguez-Calderón
Israel Domínguez-Calderón
Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and during 6 weeks of post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω-3VDCa group (100 mg/kg/d LCPUFAs-ω3 + 4000 IU vitamin D + 1000 mg calcium) or the VDCa group (4000 IU vitamin D + 1000 mg calcium) for 6 weeks. Blood samples were collected to determine 25(OH)D, PTH, ICTP, and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 weeks, and 12 weeks after supplementation. The 25(OH)D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p < 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p = 0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω-3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p = 0.024). Conclusions: Combined omega-3 and 4000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.

5 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
MLMardia López-Alarcón
Mardia López-Alarcón
VVVíctor Saul Vital-Reyes
Víctor Saul Vital-Reyes
Eduardo Almeida-GutierrezEduardo Almeida-Gutierrez
Eduardo Almeida-Gutierrez
Jorge Maldonado-HernándezJorge Maldonado-Hernández
Jorge Maldonado-Hernández
SFSalvador Flores-Chavez
Salvador Flores-Chavez
RZRicardo Z´cruz-Lopez
Ricardo Z´cruz-Lopez
Polycystic ovary syndrome (PCOS) usually comes along with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is frequently not investigated. We evaluated 99 PCOS and 41 non-PCOS women. Clinical biomarkers of glucose-, liver-, and endothelial-related metabolic alterations were measured; participants were categorized into four groups according with obesity (OB) and hyperandrogenemia (HA) statuses: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were highly frequent in PCOS women (70%). BMI correlated with all biomarkers, while free testosterone (FT) only with glucose- and hepatic-related indicators. Despite insulin sensitivity and liver enzymes were associated with FT, women with obesity exhibited lower M [coeff = 8.56 – 0.080(FT) –3.71(Ob); p <0.001)] and higher aspartate aminotransferase (coeff = 26.27 + 0.532(FT) + 8.08(Ob); p = 0.015)] than lean at the same level of FT. Women with obesity exhibited greater risk of metabolic disorders than lean, independently of hyperandrogenemia. Clinicians are compelled to search for metabolic alterations in PCOS women; obesity must be handled in all cases, but hyperandrogenemia needs to be managed also in those with glucose- or liver-related disturbances.